首页> 外文期刊>Ophthalmology >Photorefractive keratectomy for low-to-moderate myopia and astigmatism with a small-beam, tracker-directed excimer laser.
【24h】

Photorefractive keratectomy for low-to-moderate myopia and astigmatism with a small-beam, tracker-directed excimer laser.

机译:使用小光束,跟踪器定向的准分子激光进行屈光性角膜切除术,用于中低度近视和散光。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To assess the safety and effectiveness of the Autonomous Technologies Corporation LADARVision excimer laser system for photorefractive keratectomy correction of myopia and astigmatism. DESIGN: A multicenter, prospective, noncomparative case series. PARTICIPANTS: The cohort consisted of 467 eyes corrected for spherical myopia and 211 eyes corrected for myopia with astigmatism. INTERVENTION: Treatments were performed at six sites in the United States using a 6-mm ablation zone for spherical myopes and a 5.5-mm zone with a 1.0-mm blend for astigmats. MAIN OUTCOME MEASURES: Visual acuity, subjective refraction, corneal haze, intraocular pressure, complications, adverse reactions, patient satisfaction, and corneal endothelial changes. RESULTS: Twelve-month follow-up was available on 414 spherical eyes and 175 astigmatic eyes. The results for spherical eyes with correction between -1 and -5.99 diopters (D) were: uncorrected visual acuity (UCVA) of 20/40 or better achieved by 98.1%, 20/20 or better by 72%, 1.8% lost 2 lines and 0.3% lost greater than 2 lines of best spectacle-corrected visual acuity (BSCVA); 76.4% were within 0.50 D of the target correction and 94.4% were within 1.00 D. The results for myopia with astigmatism with spherical equivalent correction between -1 and -5.99 D were: UCVA of 20/40 or better in 97.4%, 20/20 or better in 61.7%, 2.5% lost 2 lines and no eyes lost greater than 2 lines BSCVA; 73.9% were within 0.50 D of the target correction and 95% were within 1.00 D. For spherical myopes combined with myopic astigmats corrected for 6 to 10 D, results were: UCVA of 20/40 or better in 93.4%, 20/20 or better in 61.2%, 2.3% lost 2 lines and no eyes lost greater than 2 lines of BSCVA; 67.2% were within 0.50 D of the desired correction and 87.8% were within 1.00 D. Refractive stability was achieved between 3 and 6 months for the spherical and astigmatic groups. No eyes had corneal haze graded as moderate or greater, and there was no significant decrease in endothelial cell density. CONCLUSIONS: Patients treated for 1 to 10 D of spherical equivalent myopia, with or without astigmatism, showed early refractive stability, excellent UCVA, no significant loss of BSCVA, no loss of endothelial cell density, and very low levels of corneal haze to 12 months after surgery.
机译:目的:评估自治技术公司LADARVision准分子激光系统用于矫正近视和散光的屈光性角膜切除术的安全性和有效性。设计:多中心,前瞻性,非对比案例系列。参与者:该组包括467眼球状近视眼和211眼散光近视眼。干预:在美国的六个位置进行了治疗,其中球形近视使用6毫米消融区域,散光镜使用5.5毫米区域与1.0毫米混合区域进行治疗。主要观察指标:视力,主观验光,角膜混浊,眼压,并发症,不良反应,患者满意度和角膜内皮改变。结果:对414只球形眼和175只散光眼进行了12个月的随访。矫正度介于-1至-5.99的屈光度(D)的球形眼的结果是:未矫正视力(UCVA)为20/40或更高,达到98.1%,20/20或更高,达到72%,1.8%丢失2条线0.3%的患者失去了大于2线的最佳眼镜矫正视力(BSCVA); 76.4%的目标矫正度在0.50 D之内,94.4%的目标矫正度在1.00 D之内。散光近视度在-1和-5.99 D之间的球面矫正的结果是:UCVA为20/40或更高,分别为97.4%,20 / 20.或更高的占61.7%,2.5%失去了2行,并且没有眼睛损失了超过2行的BSCVA; 73.9%在目标矫正值的0.50 D之内,而95%在1.00 D之内。对于矫正了6至10 D的球形近视和近视散光,结果是:UCVA为20/40或更高,为93.4%,20/20或更好的是61.2%,有2.3%的人失去了2根视线,而没有眼睛失去了超过2根BSCVA; 67.2%在所需矫正值的0.50 D以内,87.8%在1.00 D之内。球形和散光组在3到6个月之间实现了屈光稳定性。没有眼睛的角膜混浊等级为中度或更大,并且内皮细胞密度没有显着降低。结论:接受1至10 D球形等效近视治疗的患者,无论有无散光,均表现出早期屈光稳定,出色的UCVA,无明显BSCVA损失,无内皮细胞密度损失以及极低的角膜混浊水平(至12个月)手术后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号